Class information for:
Level 1: ENDOXIFEN//TAMOXIFEN//N DESMETHYLTAMOXIFEN

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
19527 501 36.3 81%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
159 3       MENOPAUSE//ISOFLAVONES//TAMOXIFEN 61134
329 2             TAMOXIFEN//ESTROGEN RECEPTOR//AROMATASE INHIBITORS 18133
19527 1                   ENDOXIFEN//TAMOXIFEN//N DESMETHYLTAMOXIFEN 501

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ENDOXIFEN authKW 3082650 12% 82% 62
2 TAMOXIFEN authKW 790271 47% 5% 236
3 N DESMETHYLTAMOXIFEN authKW 643756 3% 81% 13
4 4 HYDROXYTAMOXIFEN authKW 459411 6% 27% 28
5 CYP2D6 authKW 361358 16% 7% 80
6 DESMETHYLTAMOXIFEN authKW 304739 1% 100% 5
7 TAMOXIFEN N OXIDE authKW 182843 1% 100% 3
8 4 HYDROXY N DESMETHYLTAMOXIFEN authKW 121896 0% 100% 2
9 GRP POLYMER MAT CONTROLLED RELEASE BIOACT CPDS BI address 121896 0% 100% 2
10 LSU STANLEY SCOTT CANC address 121896 0% 100% 2

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 2916 40% 0% 200
2 Pharmacology & Pharmacy 1679 35% 0% 174
3 Chemistry, Analytical 553 15% 0% 77
4 Biochemical Research Methods 229 8% 0% 40
5 Medical Laboratory Technology 159 3% 0% 16
6 Chemistry, Medicinal 45 4% 0% 18
7 Obstetrics & Gynecology 13 2% 0% 12
8 Toxicology 11 2% 0% 11
9 Medicine, Research & Experimental 6 3% 0% 13
10 Genetics & Heredity 6 3% 0% 15

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 GRP POLYMER MAT CONTROLLED RELEASE BIOACT CPDS BI 121896 0% 100% 2
2 LSU STANLEY SCOTT CANC 121896 0% 100% 2
3 BREAST ONCOL PROGRAM 62815 2% 10% 10
4 ADV STUDIES CATEDRA FLORENCIO TEJERINA 60948 0% 100% 1
5 ANAL ANTIDOPING 60948 0% 100% 1
6 BREAST CANC SUSCEPTIBIL PHARMACOGEN 60948 0% 100% 1
7 BREAST ZURICH 60948 0% 100% 1
8 CATEDRA FLORENCIO TEJERINA UNIV EUROPEA MADRID 60948 0% 100% 1
9 CELLULAR ST S AGE GRP 60948 0% 100% 1
10 CHAIR SEMEIOT CHIRURG 60948 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BREAST CANCER RESEARCH AND TREATMENT 17813 9% 1% 46
2 PHARMACOGENOMICS 4937 2% 1% 12
3 CANCER CHEMOTHERAPY AND PHARMACOLOGY 2105 3% 0% 16
4 CLINICAL PHARMACOLOGY & THERAPEUTICS 2032 3% 0% 14
5 PHARMACOGENETICS AND GENOMICS 1335 1% 0% 5
6 JOURNAL OF CHROMATOGRAPHY B 1314 0% 1% 2
7 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 1166 1% 0% 7
8 BREAST CANCER RESEARCH 1000 1% 0% 6
9 BREAST CARE 956 1% 1% 3
10 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 784 2% 0% 12

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ENDOXIFEN 3082650 12% 82% 62 Search ENDOXIFEN Search ENDOXIFEN
2 TAMOXIFEN 790271 47% 5% 236 Search TAMOXIFEN Search TAMOXIFEN
3 N DESMETHYLTAMOXIFEN 643756 3% 81% 13 Search N+DESMETHYLTAMOXIFEN Search N+DESMETHYLTAMOXIFEN
4 4 HYDROXYTAMOXIFEN 459411 6% 27% 28 Search 4+HYDROXYTAMOXIFEN Search 4+HYDROXYTAMOXIFEN
5 CYP2D6 361358 16% 7% 80 Search CYP2D6 Search CYP2D6
6 DESMETHYLTAMOXIFEN 304739 1% 100% 5 Search DESMETHYLTAMOXIFEN Search DESMETHYLTAMOXIFEN
7 TAMOXIFEN N OXIDE 182843 1% 100% 3 Search TAMOXIFEN+N+OXIDE Search TAMOXIFEN+N+OXIDE
8 4 HYDROXY N DESMETHYLTAMOXIFEN 121896 0% 100% 2 Search 4+HYDROXY+N+DESMETHYLTAMOXIFEN Search 4+HYDROXY+N+DESMETHYLTAMOXIFEN
9 NORENDOXIFEN 121896 0% 100% 2 Search NORENDOXIFEN Search NORENDOXIFEN
10 Z 4 HYDROXY TAMOXIFEN 121896 0% 100% 2 Search Z+4+HYDROXY+TAMOXIFEN Search Z+4+HYDROXY+TAMOXIFEN

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 BINKHORST, L , MATHIJSSEN, RHJ , JAGER, A , VAN GELDER, T , (2015) INDIVIDUALIZATION OF TAMOXIFEN THERAPY: MUCH MORE THAN JUST CYP2D6 GENOTYPING.CANCER TREATMENT REVIEWS. VOL. 41. ISSUE 3. P. 289 -299 76 84% 16
2 SCHULTINK, AHMD , ZWART, W , LINN, SC , BEIJNEN, JH , HUITEMA, ADR , (2015) EFFECTS OF PHARMACOGENETICS ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAMOXIFEN.CLINICAL PHARMACOKINETICS. VOL. 54. ISSUE 8. P. 797 -810 48 80% 8
3 ZEMBUTSU, H , (2015) PHARMACOGENOMICS TOWARD PERSONALIZED TAMOXIFEN THERAPY FOR BREAST CANCER.PHARMACOGENOMICS. VOL. 16. ISSUE 3. P. 287 -296 51 68% 4
4 CRONIN-FENTON, DP , DAMKIER, P , LASH, TL , (2014) METABOLISM AND TRANSPORT OF TAMOXIFEN IN RELATION TO ITS EFFECTIVENESS: NEW PERSPECTIVES ON AN ONGOING CONTROVERSY.FUTURE ONCOLOGY. VOL. 10. ISSUE 1. P. 107 -122 53 61% 18
5 HERTZ, DL , MCLEOD, HL , IRVIN, DJ , (2012) TAMOXIFEN AND CYP2D6: A CONTRADICTION OF DATA.ONCOLOGIST. VOL. 17. ISSUE 5. P. 620-630 41 76% 30
6 JUNG, JA , LIM, HS , (2014) ASSOCIATION BETWEEN CYP2D6 GENOTYPES AND THE CLINICAL OUTCOMES OF ADJUVANT TAMOXIFEN FOR BREAST CANCER: A META-ANALYSIS.PHARMACOGENOMICS. VOL. 15. ISSUE 1. P. 49-60 43 68% 10
7 ZENG, ZY , LIU, YQ , LIU, ZM , YOU, JP , CHEN, ZP , WANG, J , PENG, QL , XIE, L , LI, RL , LI, S , ET AL (2013) CYP2D6 POLYMORPHISMS INFLUENCE TAMOXIFEN TREATMENT OUTCOMES IN BREAST CANCER PATIENTS: A META-ANALYSIS.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 72. ISSUE 2. P. 287-303 41 75% 9
8 HENNIG, EE , PIATKOWSKA, M , KARCZMARSKI, J , GORYCA, K , BREWCZYNSKA, E , JAZWIEC, R , KLUSKA, A , OMIOTEK, R , PAZIEWSKA, A , DADLEZ, M , ET AL (2015) LIMITED PREDICTIVE VALUE OF ACHIEVING BENEFICIAL PLASMA (Z)-ENDOXIFEN THRESHOLD LEVEL BY CYP2D6 GENOTYPING IN TAMOXIFEN-TREATED POLISH WOMEN WITH BREAST CANCER.BMC CANCER. VOL. 15. ISSUE . P. - 33 85% 4
9 KARLE, J , BOLBRINKER, J , VOGL, S , KREUTZ, R , DENKERT, C , EUCKER, J , WISCHNEWSKY, M , POSSINGER, K , REGIERER, AC , (2013) INFLUENCE OF CYP2D6-GENOTYPE ON TAMOXIFEN EFFICACY IN ADVANCED BREAST CANCER.BREAST CANCER RESEARCH AND TREATMENT. VOL. 139. ISSUE 2. P. 553-560 36 82% 5
10 OPDAM, FL , DEZENTJE, VO , DEN HARTIGH, J , MODAK, AS , VREE, R , BATMAN, E , SMORENBURG, CH , NORTIER, JWR , GELDERBLOM, H , GUCHELAAR, HJ , (2013) THE USE OF THE C-13-DEXTROMETHORPHAN BREATH TEST FOR PHENOTYPING CYP2D6 IN BREAST CANCER PATIENTS USING TAMOXIFEN: ASSOCIATION WITH CYP2D6 GENOTYPE AND SERUM ENDOXIFEN LEVELS.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 71. ISSUE 3. P. 593-601 35 80% 11

Classes with closest relation at Level 1


Rank Class id link
1 6521 TAMOXIFEN//TOREMIFENE//ANTIESTROGEN
2 5771 ANTIESTROGEN//ANTIESTROGEN BINDING SITES//AEBS
3 4960 AROMATASE INHIBITORS//AROMATASE INHIBITOR//ANASTROZOLE
4 1626 CYP2D6//DEBRISOQUINE//CYP2D6 POLYMORPHISM
5 10428 BAZEDOXIFENE//RALOXIFENE//TISSUE SELECTIVE ESTROGEN COMPLEX
6 5097 AROMATASE INHIBITORS//ANASTROZOLE//EXEMESTANE
7 32633 THIOSENS//PHARMACOL CELLULAIRE MOL ANTICANC//ALPHANIZOMENON FLOS AQUAE
8 8662 PHARMACOGENOMICS//HLA B5701//PERSONALIZED MEDICINE
9 7620 FULVESTRANT//ENDOCRINE RESISTANCE//FASLODEX
10 14933 CYP1B1//CYP2S1//CYP2W1

Go to start page